Trial Profile

A phase III pivotal study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabodenoson (Primary)
Indications Ocular hypertension; Open-angle glaucoma
Focus Therapeutic Use
Sponsors Inotek Pharmaceuticals

Most Recent Events

31 Mar 2015 Inotek Pharmaceuticals expects to begin this trial in early 2017. If the primary objectives of phase III program are met, then Inotek Pharmaceuticals will submit a NDA to the US FDA for marketing approval of Trabodenoson for glaucoma in the USA and then submit a MAA in Europe subsequently, according to the company SEC filing report 10-K 2014.
31 Mar 2015 New trial record created.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com